NEW YORK (
CHANGE IN RATINGS
(AMZN - Get Report)
was downgraded at Bank of America/Merrill Lynch to Neutral. Valuation call, based on a $235 price target, BofA/Merrill said.
Abercrombie & Fitch
was upgraded at Brean Murray from Hold to Buy. $65 price target. Estimates also boosted, as business trends appear to have bottomed, Brean Murray said.
Addus Homecare Corp.
was upgraded to hold at TheStreet Ratings.
was upgraded at JP Morgan from Neutral to Overweight. Valuation call, as the stock has seen a sharp selloff in recent weeks, JP Morgan said.
was upgraded at Deutsche Bank to Buy from Hold. $131 price target. Concho has underperformed its peers 13% year to date on unwarranted concerns, Deutsche Bank said.
was downgraded at Citigroup to Neutral from Buy. $66 price target. Rally suggests the coatings valuation bar has been raised, Citigroup said.
was downgraded at JP Morgan to Neutral. Valuation call, as the stock is up 38% year-to-date, JP Morgan said.
(FTR - Get Report)
was upgraded at Nomura from Neutral to Buy. $5 price target. Stock is attractively valued, with a 10% dividend and 20% free cash flow yield, Nomura said.
GAIN Capital Holdings
was downgraded to sell at TheStreet Ratings.
(GRPN - Get Report)
was downgraded from Hold to Sell at Stifel Nicolaus. Business model remains a work in progress, Stifel Nicolaus said.
(GRPN - Get Report)
was downgraded from Buy to Neutral at Bank of America/Merrill Lynch. Restatement undermines investor confidence, BofA/Merrill said. $20 price target.
was upgraded at JP Morgan from Underweight to Neutral. $55 price target. Stock has underperformed its peers over the past five months, JP Morgan said.
was downgraded at UBS to Neutral from Buy. $35 price target. Valuation ahead of fundamentals, UBS said.
was downgraded at Sterne Agee to Underperform from Neutral. $24.50 price target. Guidance unlikely to support recent outperformance, Sterne Agee said.
was upgraded at Credit Suisse from Neutral to Outperform. Demand is improving in the U.S. and Europe, Credit Suisse said. $105 price target.
was initiated with a Buy rating at Goldman Sachs. $144 price target. Anticipate continued robust uptake of new drug Eylea, Goldman said.
SL Green Realty
was downgraded at UBS to Neutral from Buy. $80 price target. Lacking meaningful positive catalysts, UBS said.